REGULATORY

Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision

March 4, 2022
Japan’s health ministry on March 4 announced new NHI prices for listed medicines, effective April 1, revealing a 15.8% slash for Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan), and up to 11.1% for injectable GLP-1 agents. The Ministry of Health, Labor…

To read the full story

Related Article

REGULATORY

By Yoshinori Sagehashi

“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…

By Philip Carrigan

Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…

Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…